Abbonarsi

AUTOIMMUNE LIVER DISEASE : Current Standards, Future Directions - 03/09/11

Doi : 10.1016/S1089-3261(05)70167-7 
Robert G. Gish, MD a, Andrew Mason, MD b
a Departments of Medicine and Transplantation, California Pacific Medical Center, San Francisco, California (RGG) 
b Department of Medicine, Section of Gastroenterology and Hepatology, Ochsner Clinic and Medical Foundation, New Orleans, Louisiana (AM) 

Riassunto

Autoimmune hepatitis (AIH) comprises a relatively diverse group of liver diseases associated with autoantibody formation (Figure 1) which are thought to occur as a result of an uncontrolled, self-directed inflammatory attack on hepatocytes or bile ducts. The immune injury commonly leads to rapidly progressive liver disease, progressive fibrosis, and ultimately cirrhosis. The cause of autoimmune liver disease is not known, but factors that influence the development of clinical disease include genetic predisposition, prior liver injury caused by viruses, environmental exposure to toxins, and, possibly, ongoing infectious factors, including viruses.

The incidence and prevalence of the forms of autoimmune liver diseases remain to be defined worldwide, although information is available for distinct ethnic populations.27 The point prevalence of autoimmune liver disease ranges from 13 to 20/100,000 population and the incidence from 1 to 2/100,000 in a Norwegian population.35

Improving the understanding of autoimmune liver disease will allow physicians and other medical practitioners to make decisions about the proper type of therapy to prevent progressive liver disease and may ultimately eliminate death from liver failure and the need for liver transplantation. Other focuses of therapy include improving quality of life preventing primary septic complications caused by biliary strictures (in primary sclerosing cholangitis) and infectious complications of immune suppression.

Serologic assays, biochemical tests, histologic criteria, and imaging tests have provided the basis for the diagnosis of autoimmune liver disease. Recent advances in serologic testing, genetic studies, and immunohistochemistry may provide more rapid and accurate diagnosis of patients with autoimmune liver disease and may also guide the cause of immunosuppressive therapy.

Infectious causes of autoimmune liver disease have been proposed, with prior viral hepatitis A, B, or C, cytomegalovirus (CMV), paramyxovirus, and most recently retrovirus infections suggested as possibilities.108, 111 The development of recurrent AIH, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) in liver transplant recipients provides strong support for an infectious origin for of these disorders. If environmental agents are found to be the cause or a component of disease activity and progression, advances in antibiotic and antiviral therapies may also delay or prevent progressive liver disease.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Robert G. Gish, MD 2340 Clay Street Room 223 California Pacific Medical Center San Francisco, CA 94115 e-mail: [email protected]
Financial Support: ALM supported by a Hepatology Seed Grant for Primary Biliary Cirrhosis from the American Liver Foundation, and AI01467 from the National Institute for Health.


© 2001  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.© 1993 
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 5 - N° 2

P. 287-314 - maggio 2001 Ritorno al numero
Articolo precedente Articolo precedente
  • PREFACE
  • ROBERT G. GISH
| Articolo seguente Articolo seguente
  • HEPATIC FIBROSIS : Pathogenesis and Principles of Therapy
  • Efsevia Albanis, Scott L. Friedman

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.